Neurodegenerative disorders

PET imaging of tau pathology wins FDA approval for AD diagnosis

PET imaging for tau pathology has won regulatory approval in the US for assisting the diagnosis of Alzheimer’s disease. The Food and Drug Administration (FDA) has approved a radioactive diagnostic agent flortaucipir F18 (Tauvid, Eli Lilly) intravenous injection for use with PET imaging of the brain to estimate the density and distribution of aggregated tau ...

Already a member?

Login to keep reading.

© 2021 the limbic